Comment

Materializing the future of vaccines and immunotherapy

Materials science has the potential to overcome some of the grand challenges facing the fields of immunology and immunotherapy. The floodgates are poised to open.

  • Subscribe to Nature Reviews Materials for full access:

    $59

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

References

  1. 1.

    , & Cancer immunotherapy comes of age. Nature 480, 480–489 (2011).

  2. 2.

    & Engineering materials for cancer immunotherapy. Nano Today (2015).

  3. 3.

    & HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol. Rev. 254, 225–244 (2013).

  4. 4.

    , & Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life. Curr. Opin. HIV AIDS 10, 160–169 (2015).

  5. 5.

    et al. Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease. Nat. Biotechnol. 31, 63–70 (2013).

Download references

Author information

Affiliations

  1. Department of Biological Engineering and Department of Materials Science & Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.

    • Darrell J. Irvine

Authors

  1. Search for Darrell J. Irvine in:

Competing interests

DJI is a co-founder of Vedantra Pharmaceuticals and Torque Biotherapeutics, and holds licensed patents in the area of vaccines and immunotherapy.

Corresponding author

Correspondence to Darrell J. Irvine.